Search results for "Dosis"

showing 10 items of 369 documents

Prognostic implications of arterial blood gases in acute decompensated heart failure

2010

The prognostic value of arterial blood gases (ABG) in patients with acute decompensated heart failure (ADHF) is not well-established. We therefore conducted the present study to determine the relationship between ABG on admission and long-term mortality in patients with ADHF.We studied 588 patients consecutively admitted to our department with ADHF. ABG and classical prognostic variables were determined at patients' arrival to the emergency department. The independent association among the main variables of ABG (pO2, pCO2 and pH) and mortality was assessed with Cox regression analysis.At a median follow-up of 23months, 221 deaths (37.6%) were registered. 308 (52.4%), 54 (9.2%) and 50 (8.5%)…

MalePrognostic variablemedicine.medical_specialtyAcute decompensated heart failureHyperoxiaSeverity of Illness IndexVentricular Function LeftpCO2HypoxemiaCause of DeathInternal medicineInternal MedicinemedicineHumansHypoxiaAgedRetrospective StudiesAcidosisHeart FailureProportional hazards modelbusiness.industryEmergency departmentCarbon DioxidePrognosismedicine.diseaseOxygenSurvival RateSpainCardiologyArterial bloodBlood Gas Analysismedicine.symptombusinessFollow-Up StudiesEuropean Journal of Internal Medicine
researchProduct

Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 20…

2020

Artículo con numerosos autores. Sólo se hace referencia al primero que coincide con el de la UAM y al colectivo

MaleRespiratory diseasesRespiratory Tract DiseasesDiseaseChronic respiratory diseasesGlobal Burden of DiseasePulmonary Disease Chronic Obstructive0302 clinical medicineCost of Illness11. SustainabilityMETABOLIC RISKSEPIDEMIOLOGY030212 general & internal medicineChildCause of deathAged 80 and overCOPDDALYChronic obstructive pulmonary diseaseMortality rateRespiratory disease1. No povertyAge FactorsMiddle AgedDeath causes3. Good healthPREVALENCEHealth risksChild PreschoolCOMPARATIVE RISK-ASSESSMENTFemaledeath and disability worldwideQuality-Adjusted Life YearsTERRITORIESBURDENgrowth in absolute numbersPulmonary and Respiratory MedicineAdultADJUSTED LIFE-YEARSHealth burdensAdolescentMedicina195 COUNTRIESchronic respiratory diseasesArticle1117 Public Health and Health Services03 medical and health sciencesYoung AdultLife ExpectancySex FactorsBurden of Disease Respiratory diseaseSarcoidosis PulmonaryEnvironmental healthmedicineDisability-adjusted life yearHumansCOPDEXPOSURERisk factorMortalityAgedper-capita basisbusiness.industryDISABILITYInfant NewbornInfant1103 Clinical Sciencesasthmamedicine.diseaseAsthmaYears of potential life lost030228 respiratory systemRisk factors13. Climate actionSystematic analysesChronic DiseaseINJURIESHuman medicinePneumoconiosisMorbiditybusinessLung Diseases Interstitial1199 Other Medical and Health Sciences
researchProduct

IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine.

2016

BACKGROUND: IgG4-related disease is a rare, clinical and pathologic disease entity of unknown etiology. Its main features are increased serum concentrations of IgG4 > 1,35 g/l, lymphocyte and IgG4+plasma-cell infiltration within tissues, fibrosis or sclerosis. The classical presentation of IgG4-RSD is pancreatitis which is combined with the involvement of biliary ducts in 74 percent of patients. Extrapancreatic manifestations include: abdominal or mediastinal lymphadenopathy; the involvement of salivary glands and lacrimal glands, kidneys, lung, retroperitoneum. Since IgG4-related disease is a multiorgan lymphoproliferative syndrome, it requires a careful differential diagnosis from othe…

MaleSystemic diseasePathologymedicine.medical_specialtySettore MED/09 - Medicina InternaCholangitis SclerosingLymphadenopathyAzathioprineRetroperitoneal fibrosisSialadenitisIgG4 syndrome Internal MedicineDrug DiscoveryInternal MedicinemedicineHumansEosinophiliaAgedPharmacologybusiness.industryRetroperitoneal FibrosisSyndromemedicine.diseaseImmunoglobulin GPancreatitisIgG4-related diseaseSarcoidosismedicine.symptomDifferential diagnosisbusinessmedicine.drug
researchProduct

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area

2016

Tafamidis is a transthyretin (TTR) stabilizer able to prevent TTR tetramer dissociation. There have been a few encouraging studies on Tafamidis efficacy in early-onset inherited transthyretin amyloidosis (ATTR) due to Val30Met mutation. However, less is known about its efficacy in later disease stages and in non-Val30Met mutations. We performed a multi-center observational study on symptomatic ATTR patients prescribed to receive Tafamidis. We followed up patients according to a standardized protocol including general medical, cardiological and neurological assessments at baseline and every 6 months up to 3 years. Sixty-one (42 males) patients were recruited. Only 28 % of enrolled subjects h…

MaleTafamidisAmyloid polyneuropathyNeurologyCardiomyopathyDisease030204 cardiovascular system & hematologySeverity of Illness IndexTransthyretinchemistry.chemical_compound0302 clinical medicinePrealbuminTafamidiLongitudinal StudiesStage (cooking)Aged 80 and overBenzoxazolesbiologyAmyloidosisMiddle Agedamyloid polyneuropathy; tafamidis; transthyretinPrognosisTafamidisSettore MED/26 - NEUROLOGIATreatment OutcomeItalyNeurologyDisease ProgressionFemaleAmyloid polyneuropathy; Tafamidis; Transthyretin; Neurology (clinical); NeurologyAdultmedicine.medical_specialty03 medical and health sciencesInternal medicineSeverity of illnessmedicineHumansAgedAmyloid Neuropathies Familialbusiness.industrynutritional and metabolic diseasesmedicine.diseaseSurgeryTransthyretinchemistryMutationbiology.proteinNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of Neurology
researchProduct

Deletion of the Hunter gene and both DXS466 and DXS304 in a patient with mucopolysaccharidosis type II.

1992

Hunter syndrome is an X-linked mucopoly-saccharidosis due to deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS). A cDNA clone containing the entire coding region of the human IDS gene, mapped in Xq28, has been used as molecular probe to study a patient with Hunter syndrome. A submicroscopic deletion has been detected that spans the IDS gene as well as DXS466 and DXS304, 2 loci mapped probably not more than 900 kb from the IDS locus. A detailed clinical description of the patient is provided and his phenotype is compared to that of other patients with IDS deletion described recently. By following the segregation of a restriction fragment length polymorphism at the IDS locus in th…

MaleX ChromosomeLocus (genetics)Iduronate SulfataseBiologyGene mappingmedicineHumansMucopolysaccharidosis type IIChildGenetics (clinical)X chromosomeMucopolysaccharidosis IIGeneticsIduronate-2-sulfataseChromosome MappingHunter syndromeDNAmedicine.diseaseXq28PedigreeBlotting SouthernFemaleRestriction fragment length polymorphismChromosome DeletionPolymorphism Restriction Fragment LengthAmerican journal of medical genetics
researchProduct

Gene diagnosis and carrier detection in Hunter syndrome by the iduronate-2-sulphatase cDNA probe.

1992

Hunter disease (McKusick 309900) is an X-chromosomal mucopolysaccharidosis due to deficiency of the lysosomal enzyme iduronate-2-sulphatase (IDS; EC 3.1.6.13). Diagnosis is based on both the typical clinical features of patients and the lack/reduction of IDS activity. Female carriers show no symptoms of the disease. In the past, several different assays were elaborated for measuring enzyme activity in carriers but none of them proved to be suitable for detecting heterozygotes reliably (Zlotogora and Bach 1984)

MaleX ChromosomeMucopolysaccharidosisIduronate SulfataseBiologyGene mappingComplementary DNAGenotypeGeneticsmedicineHumansAlleleChildDeoxyribonucleases Type II Site-SpecificGenetics (clinical)Mucopolysaccharidosis IIGeneticsGenetic Carrier ScreeningHunter syndromeHeterozygote advantagemedicine.diseaseMolecular biologyEnzyme assayPedigreeBlotting Southernbiology.proteinDNA ProbesPolymorphism Restriction Fragment LengthJournal of inherited metabolic disease
researchProduct

Molecular analysis in patients with mucopolysaccharidosis type II suggests that DXS466 maps within the Hunter gene

1993

Hunter disease is an X-linked mucopolysaccharidosis caused by deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS). Using the IDS cDNA and DNA probes corresponding to loci flanking the IDS locus, we performed molecular genetic studies in two patients with Hunter syndrome. An interstitial deletion spanning the middle part of the IDS gene was found in the first patient. The second patient carries a gross gene rearrangement that can be detected after HindIII or EcoRI digestion of genomic DNA, and is similar to that found recently in seven unrelated Hunter patients. Our data suggest that the structural aberration observed is a partial intragenic inversion. As the same altered hybridiz…

MaleX ChromosomeRestriction MappingLocus (genetics)Iduronate SulfataseHindIIIDeoxyribonuclease EcoRIGeneticsmedicineHumansMucopolysaccharidosis type IIChildDeoxyribonucleases Type II Site-SpecificGenetics (clinical)Mucopolysaccharidosis IIGeneticsbiologyHybridization probeHunter syndromeGene rearrangementmedicine.diseaseMolecular biologyBlotting Southerngenomic DNAChild Preschoolbiology.proteinRestriction fragment length polymorphismDNA ProbesPolymorphism Restriction Fragment LengthHuman Genetics
researchProduct

Cumulative incidence rates of the mucopolysaccharidoses in Germany

2005

In order to estimate the cumulative incidence rates of the mucopolysaccharidoses (MPS) in Germany, a retrospective epidemiological survey covering the period between 1980 and 1995 was implemented. Multiple ascertainment sources were used to identify affected patients. A prevalence of approximately 0.69 cases per 100,000 births was obtained for MPS I (Hurler phenotype). Within the study period, 4 patients with Hurler/Scheie phenotype and 7 cases with Scheie disease were detected. The cumulative incidence for MPS II (Hunter syndrome) was estimated as 0.64 cases per 100,000 births (1.3 cases per 100,000 male live births); that for MPS III (Sanfilippo syndrome types A, B and C) as 1.57 cases in…

Malecongenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtyMorquio syndromeGenotypeTurkeyMucopolysaccharidosisMucopolysaccharidosis type IIIGermanyGeneticsmedicineHumansCumulative incidenceMucopolysaccharidosis type IIskin and connective tissue diseasesGenetics (clinical)Retrospective StudiesSanfilippo syndromebusiness.industryIncidenceIncidence (epidemiology)nutritional and metabolic diseasesHunter syndromeMucopolysaccharidosesHospital Recordsbeta-Galactosidasemedicine.diseasePhenotypeFemalebusinessJournal of Inherited Metabolic Disease
researchProduct

Aplasia of the retinal vessels combined with optic nerve hypoplasia, neonatal epileptic seizures, and lactic acidosis due to mitochondrial complex I …

1992

A newborn male with mitochondrial complex I deficiency suffered from neonatal epileptic seizures, which later developed into infantile spasms. The infant was blind due to aplasia of the retinal vessels and hypoplasia of the optic nerve. There was congenital lactic acidosis, which persisted in later life. The boy was microcephalic and retarded. Muscular hypotonia later shifted to spasticity. Succinic acid was increased in urine. We assume that the aplasia of the retinal vessels is due to damage of the retinal ganglion cells caused by the mitochondrial disease in the first 3 to 4 months of pregnancy.

Malecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyCongenital lactic acidosisRetinal ganglionInternal medicineMedicineHumansNADH NADPH OxidoreductasesOptic nerve hypoplasiaRetinaElectron Transport Complex IEpilepsybusiness.industryInfant NewbornBrainRetinal VesselsOptic NerveAplasiamedicine.diseaseHypoplasiaMitochondriabody regionsEndocrinologymedicine.anatomical_structureLactic acidosisPediatrics Perinatology and Child HealthOptic nerveAcidosis LacticbusinessTomography X-Ray ComputedEuropean journal of pediatrics
researchProduct

Hunter disease before and during enzyme replacement therapy.

2011

Mucopolysaccharidosis type II (Hunter disease) is a lysosomal storage disease attributable to X-linked deficiency of the enzyme α-L-iduronate-sulfatase. Because of this deficiency, glycosaminoglycanes accumulate in various tissues and body fluids. We describe three patients representing the broad spectrum of Hunter disease and their response to enzyme replacement therapy. Patient 1 did not manifest central nervous system involvement, patient 2 manifested moderate neurologic disease, and patient 3 had already manifested a severe neurologic course during early infancy. In all patients, improvements in visceral organ size, physical capacity, and gastrointestinal functioning were reported. More…

Malemedicine.medical_specialtyAdolescentmedicine.drug_classAntibioticsCentral nervous systemIduronate SulfataseBiologyGastroenterologyFrameshift mutationYoung AdultDevelopmental NeuroscienceInternal medicinemedicineLysosomal storage diseaseMissense mutationHumansEnzyme Replacement TherapyMucopolysaccharidosis type IIYoung adultChildGlycosaminoglycansMucopolysaccharidosis IIInfant NewbornInfantEnzyme replacement therapyOrgan Sizemedicine.diseaseSurgeryGastrointestinal Tractmedicine.anatomical_structureNeurologyChild PreschoolPediatrics Perinatology and Child HealthNeurology (clinical)Nervous System DiseasesPediatric neurology
researchProduct